Celastrol inhibits the production of proinflammatory cytokines in the testicular tissue by specifically targeting the TLR4/MyD88/NF- κB signaling cascade pathways. This indicates that celastrol may serve as a promising new therapeutic target for treating diabetic reproductive dysfunction.
Introduction: Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders with poor social interaction, communication issues, aberrant motor movements, and limited repetitive interests and behaviour. Spirulina platensis (SP) contains several multi-nutrients and has a wide range of neuroprotective properties.Aim: The target of the current experiment is to detect the protective effects of S. platensis on valproic-induced autism in adult female albino rats' siblings for the first time.Materials and Methods: Twelve Pregnant rats were separated into four main groups; Group I (control); Group II (S. platensis); Group III (autistic group); and Group IV (autistic SP-treated group). Fifteen offspring pups from each group were sacrificed, brain was divided for biochemical analysis as superoxide dismutase and malondialdehyde were evaluated spectrophotometrically while interleukin-6, interleukin-12, Bcl-2-associated X protein, B-cell lymphoma-2, Beclin-1, brain-derived neurotrophic factor were assessed by ELISA, other division of brain were used for gene expression of PI3k, Akt and mTOR pathway, last division of brain were stained using (H&E) and Giemsa stains. Tumour necrosis factor alpha (TNF- and Synaptophysin (SYN) markers were used for immunohistochemical staining.Results: Autistic Group (III) showed an increment in levels of MDA, IL-6, IL12 and BAX while showing a decrement in SOD, Bcl-2 and Beclin-1 as well as increased PI3k, Akt and mTOR gene expression. Autistic Group (III) also exhibited hypocellularity and disorganization of hippocampal and prefrontal cortex cells. The autistic SP-treated group (IV) showed improvement in these biochemical markers and pathological changes. Our findings suggest that Spirulina platensis will be significant in managing autism.
Most patients with idiopathic intracranial hypertension (IIH) have venous sinus stenosis. In the previous decade, venous sinus stenting has emerged as an ultimate treatment for resistant or refractory cases with IIH. However, studies in this regard are relatively few, especially from lower income countries. We aimed to evaluate the feasibility and efficacy of venous sinus stenting in our tertiary center. We retrospectively reviewed our prospectively collected database from January 2021 to January 2023 and recruited eligible patients with IIH and venous sinus stenosis who underwent stenting. We recruited 113 patients, all of them were females with a mean age of 30 ± 8 years and mean BMI of 30 ± 3.1. Stenting was technically successful in all our patients. Post stenting angioplasty was warranted in three cases (2.6%). Complications occurred in one case (0.9%) in the form of a rim of subdural hematoma without any clinical sequelae. At 3 months follow-up, 93 patients (82.3%) experienced complete relief of their symptoms, whereas 11 patients (9.7%) still had headache without papilledema and 9 patients (8%) had papilledema. Seven patients (6.2%) received ventriculoperitoneal shunting and two patients (1.8%) experienced restenosis and received another stenting procedure. Stenting of the venous sinus stenosis in IIH patients is effective and safe treatment and can be accomplished with a very low complication rate and relatively higher success rate.
2 March 2025 in Journal of Biochemical and Molecular Toxicology